Imfinzi (durvalumab)
MarketedAn immuno-oncology medicine; from March 2026 Korean national health insurance covers its first-line use in unresectable biliary tract cancer and advanced hepatocellular carcinoma.
FROM PUBLIC EVENTS · 2026-11-18
Commercial · sales Supplies oncology and respiratory medicines in Korea while widening reimbursement, launching new products and running partnership programs with Korean biotechs.
Roles often seen at this stageSales & marketing · Medical & MSL · Regulatory affairs
The Korean affiliate of AstraZeneca, supplying oncology, respiratory and other prescription medicines in Korea; certified as an Innovative Pharmaceutical Company by the Ministry of Health and Welfare in 2018 and recertified in 2021 and 2024.
An immuno-oncology medicine; from March 2026 Korean national health insurance covers its first-line use in unresectable biliary tract cancer and advanced hepatocellular carcinoma.
A COPD maintenance inhaler combining an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist; launched in Korea in April 2026.
A program run with the Seoul city government and Seoul Bio Hub that selects Korean biotech startups and gives them R&D mentoring, a chance to join AstraZeneca's BioVentureHub in Gothenburg, Sweden, and 35 million won of research funding each.
Selected two companies, Avatar Therapeutics and Curogen, from 33 applicants to its global open innovation program with Seoul Bio Hub.
Imfinzi became reimbursed for first-line biliary tract cancer and hepatocellular carcinoma in Korea.
Announced the Korean launch of the triple-therapy COPD inhaler Breztri Aerosphere.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.